Bioatla Inc Total Liabilities
Bioatla Inc total liabilities. Based on the latest financial reports, Bioatla Inc (BCAB) has total liabilities worth $45.88 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Bioatla Inc working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Total Liabilities of Bioatla Inc (2018–2025)
Total liabilities of Bioatla Inc from 2018 to 2025. This chart illustrates how Bioatla Inc's total liabilities have evolved over time, based on quarterly financial data.
Bioatla Inc Competitors by Total Liabilities
The table below lists competitors of Bioatla Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Palatin Technologies Inc
NYSE MKT:PTN
|
USA | $10.12 Million |
|
AE Multi Holdings Bhd
KLSE:7146
|
Malaysia | RM62.93 Million |
|
UMT United Mobility Technology AG
XETRA:UMD
|
Germany | €3.32 Million |
|
Henry Boot PLC
LSE:BOOT
|
UK | GBX208.79 Million |
|
Whitehawk Ltd
AU:WHK
|
Australia | AU$255.81K |
|
Southern Empire Resources Corp
V:SMP
|
Canada | CA$2.44 Million |
|
Geekco Technologies Corp
V:GKO
|
Canada | CA$2.55 Million |
|
20/20 Biolabs, Inc. Common Stock
NASDAQ:AIDX
|
USA | $3.13 Million |
Liability Composition Analysis (2018–2025)
This chart breaks down Bioatla Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see BCAB total assets.
Liquidity & Leverage Metrics
Bioatla Inc Total Liabilities Ratios Explained
Bioatla Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.15 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 5.36 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bioatla Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bioatla Inc (2018–2025)
The table below shows the annual total liabilities of Bioatla Inc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $50.02 Million | +31.08% |
| 2024-12-31 | $38.16 Million | -22.11% |
| 2023-12-31 | $48.99 Million | +7.91% |
| 2022-12-31 | $45.40 Million | +4.12% |
| 2021-12-31 | $43.60 Million | +24.71% |
| 2020-12-31 | $34.96 Million | -46.50% |
| 2019-12-31 | $65.35 Million | +44.95% |
| 2018-12-31 | $45.08 Million | -- |
About Bioatla Inc
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); a… Read more